Skip to main content
. 2016 Dec 19;28(3):642–650. doi: 10.1093/annonc/mdw670

Figure 1.

Figure 1.

(A) Among the 121 patients whose cfDNA samples were tested for KRASG12/G13 mutations, the median overall survival (OS) duration of the 82 patients with a KRASG12/G13-mutant cfDNA percentage of <6.2% (7.5 months; 95% confidence interval [CI], 5.6–9.4 months; blue) was significantly longer than that of the 39 patients with a KRASG12/G13-mutant cfDNA percentage of ≥6.2% (5.4 months; 95% CI, 3.7–7.1; red; P = 0.001). (B) In a separate analysis that included only the 88 patients with KRASG12/G13 mutations in formalin-fixed, paraffin-embedded tumor samples, the median OS duration of the 44 patients with a KRASG12/G13-mutant cfDNA percentage of <4.0% (7.3 months; 95% CI, 3.6–11.0; blue) was significantly longer than that of the 44 patients with a KRASG12/G13-mutant cfDNA percentage of ≥4.0% (5.5 months; 95% CI, 4.3–6.7; red; P = 0.017).